AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
SEQUENCE-DEPENDENT HEMATOLOGICAL TOXICITY ASSOCIATED WITH THE 3-HOUR PACLITAXEL CYCLOPHOSPHAMIDE DOUBLET/
Authors: KENNEDY MJ ZAHURAK ML DONEHOWER RC NOE D GROCHOW LB SARTORIUS S CHEN TL BOWLING K DUERR M ROWINSKY EK
Citation: Mj. Kennedy et al., SEQUENCE-DEPENDENT HEMATOLOGICAL TOXICITY ASSOCIATED WITH THE 3-HOUR PACLITAXEL CYCLOPHOSPHAMIDE DOUBLET/, Clinical cancer research, 4(2), 1998, pp. 349-356
SEQUENCE-DEPENDENT HEMATOLOGICAL TOXICITY ASSOCIATED WITH THE 3-HOUR PACLITAXEL CYCLOPHOSPHAMIDE DOUBLET/
Authors: KENNEDY MJ ZAHURAK ML DONEHOWER RC NOE D GROCHOW LB SARTORIUS S CHEN TL BOWLING K DUERR M ROWINSKY EK
Citation: Mj. Kennedy et al., SEQUENCE-DEPENDENT HEMATOLOGICAL TOXICITY ASSOCIATED WITH THE 3-HOUR PACLITAXEL CYCLOPHOSPHAMIDE DOUBLET/, Clinical cancer research, 4(2), 1998, pp. 349-356
A PHASE-II WINDOW STUDY OF TOPOTECAN IN UNTREATED PATIENTS WITH HIGH-RISK ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: GORE SD ROWINSKY EK MILLER CB GRIFFIN C CHEN TL BOROWITZ M DONEHOWER RC BURKS KL ARMSTRONG DK BURKE PJ GREVER MR KAUFMANN SH
Citation: Sd. Gore et al., A PHASE-II WINDOW STUDY OF TOPOTECAN IN UNTREATED PATIENTS WITH HIGH-RISK ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA, Clinical cancer research, 4(11), 1998, pp. 2677-2689
HIGH-DOSE TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN FLUOROPYRIMIDINE-REFRACTORY COLORECTAL-CANCER - A PHASE-II AND PHARMACODYNAMIC STUDY
Authors: ROWINSKY EK BAKER SD BURKS K OREILLY S DONEHOWER RC GROCHOW LB
Citation: Ek. Rowinsky et al., HIGH-DOSE TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN FLUOROPYRIMIDINE-REFRACTORY COLORECTAL-CANCER - A PHASE-II AND PHARMACODYNAMIC STUDY, Annals of oncology, 9(2), 1998, pp. 173-180
A PHASE-I AND PHARMACOLOGICAL STUDY OF DMP-840 ADMINISTERED BY 24-HOUR INFUSION
Authors: OREILLY S BAKER SD SARTORIUS S ROWINSKY EK FINIZIO M LUBINIECKI GM GROCHOW LB GRAY JE PIENIASZEK HJ DONEHOWER RC
Citation: S. Oreilly et al., A PHASE-I AND PHARMACOLOGICAL STUDY OF DMP-840 ADMINISTERED BY 24-HOUR INFUSION, Annals of oncology, 9(1), 1998, pp. 101-104
CYTOTOXIC SYNERGY BETWEEN PYRAZOLOACRIDINE (NSC-366140) AND CISPLATININ-VITRO - INHIBITION OF PLATINUM-DNA ADDUCT REMOVAL
Authors: ADJEI AA BUDIHARDJO II ROWINSKY EK KOTTKE TJ SVINGEN PA BUCKWALTER CA GROCHOW LB DONEHOWER RC KAUFMANN SH
Citation: Aa. Adjei et al., CYTOTOXIC SYNERGY BETWEEN PYRAZOLOACRIDINE (NSC-366140) AND CISPLATININ-VITRO - INHIBITION OF PLATINUM-DNA ADDUCT REMOVAL, Clinical cancer research, 3(5), 1997, pp. 761-770
PHASE-I AND PHARMACOLOGICAL STUDY OF CI-980, A NOVEL SYNTHETIC ANTIMICROTUBULE AGENT
Authors: ROWINSKY EK LONG GS NOE DA GROCHOW LB BOWLING MK SARTORIUS SE DONEHOWER RC
Citation: Ek. Rowinsky et al., PHASE-I AND PHARMACOLOGICAL STUDY OF CI-980, A NOVEL SYNTHETIC ANTIMICROTUBULE AGENT, Clinical cancer research, 3(3), 1997, pp. 401-407
PHASE-I AND PHARMACOLOGICAL STUDY OF PENCLOMEDINE, A NOVEL ALKYLATINGAGENT, IN PATIENTS WITH SOLID TUMORS
Authors: OREILLY S GROCHOW LB DONEHOWER RC CHEN TL BOWLING K HARTMAN NR STRUCK RF ROWINSKY EK
Citation: S. Oreilly et al., PHASE-I AND PHARMACOLOGICAL STUDY OF PENCLOMEDINE, A NOVEL ALKYLATINGAGENT, IN PATIENTS WITH SOLID TUMORS, Journal of clinical oncology, 15(5), 1997, pp. 1974-1984
PHASE-I AND PHARMACOLOGICAL STUDIES OF TOPOTECAN IN PATIENTS WITH IMPAIRED HEPATIC-FUNCTION
Authors: OREILLY S ROWINSKY E SLICHENMYER W DONEHOWER RC FORASTIERE A ETTINGER D CHEN TL SARTORIUS S BOWLING K SMITH J BRUBAKER A LUBEJKO B IGNACIO V GROCHOW LB
Citation: S. Oreilly et al., PHASE-I AND PHARMACOLOGICAL STUDIES OF TOPOTECAN IN PATIENTS WITH IMPAIRED HEPATIC-FUNCTION, Journal of the National Cancer Institute, 88(12), 1996, pp. 817-824
CYTOTOXIC EFFECTS OF TOPOTECAN COMBINED WITH VARIOUS ANTICANCER AGENTS IN HUMAN CANCER CELL-LINES
Authors: KAUFMANN SH PEEREBOOM D BUCKWALTER CA SVINGEN PA GROCHOW LB DONEHOWER RC ROWINSKY EK
Citation: Sh. Kaufmann et al., CYTOTOXIC EFFECTS OF TOPOTECAN COMBINED WITH VARIOUS ANTICANCER AGENTS IN HUMAN CANCER CELL-LINES, Journal of the National Cancer Institute, 88(11), 1996, pp. 734-741
TISSUE AND TUMOR DISTRIBUTION OF C-14 PENCLOMEDINE IN RATS
Authors: OREILLY S HARTMAN NR GROSSMAN SA STRONG JM STRUCK RF ELLER S LESSER GJ DONEHOWER RC ROWINSKY EK
Citation: S. Oreilly et al., TISSUE AND TUMOR DISTRIBUTION OF C-14 PENCLOMEDINE IN RATS, Clinical cancer research, 2(3), 1996, pp. 541-548
A PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN INFUSED OVER 30 MINUTES FOR 5 DAYS IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA
Authors: ROWINSKY EK KAUFMANN SH BAKER SD MILLER CB SARTORIUS SE BOWLING MK CHEN TL DONEHOWER RC GORE SD
Citation: Ek. Rowinsky et al., A PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN INFUSED OVER 30 MINUTES FOR 5 DAYS IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA, Clinical cancer research, 2(12), 1996, pp. 1921-1930
THE CLINICAL DEVELOPMENT OF PACLITAXEL - A SUCCESSFUL COLLABORATION OF ACADEMIA, INDUSTRY AND THE NATIONAL-CANCER-INSTITUTE
Authors: DONEHOWER RC
Citation: Rc. Donehower, THE CLINICAL DEVELOPMENT OF PACLITAXEL - A SUCCESSFUL COLLABORATION OF ACADEMIA, INDUSTRY AND THE NATIONAL-CANCER-INSTITUTE, Stem cells, 14(1), 1996, pp. 25-28
A PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH PREVIOUSLY UNTREATED PANCREATIC-CANCER
Authors: OREILLY S DONEHOWER RC ROWINSKY EK ORD S GROCHOW LB
Citation: S. Oreilly et al., A PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH PREVIOUSLY UNTREATED PANCREATIC-CANCER, Anti-cancer drugs, 7(4), 1996, pp. 410-414
PHASE-I AND PHARMACOLOGICAL STUDY OF HIGH-DOSES OF THE TOPOISOMERASE-I INHIBITOR TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH SOLID TUMORS
Authors: ROWINSKY EK GROCHOW LB SARTORIUS SE BOWLING MK KAUFMANN SH PEEREBOOM D DONEHOWER RC
Citation: Ek. Rowinsky et al., PHASE-I AND PHARMACOLOGICAL STUDY OF HIGH-DOSES OF THE TOPOISOMERASE-I INHIBITOR TOPOTECAN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH SOLID TUMORS, Journal of clinical oncology, 14(4), 1996, pp. 1224-1235
PHASE-I AND PHARMACOLOGICAL STUDY OF SEQUENCES OF PACLITAXEL AND CYCLOPHOSPHAMIDE SUPPORTED BY GRANULOCYTE-COLONY-STIMULATING FACTOR IN WOMEN WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER
Authors: KENNEDY MJ ZAHURAK ML DONEHOWER RC NOE DA SARTORIUS S CHEN TL BOWLING K ROWINSKY EK
Citation: Mj. Kennedy et al., PHASE-I AND PHARMACOLOGICAL STUDY OF SEQUENCES OF PACLITAXEL AND CYCLOPHOSPHAMIDE SUPPORTED BY GRANULOCYTE-COLONY-STIMULATING FACTOR IN WOMEN WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER, Journal of clinical oncology, 14(3), 1996, pp. 783-791
PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN IN PATIENTS WITH IMPAIRED RENAL-FUNCTION
Authors: OREILLY S ROWINSKY EK SLICHENMYER W DONEHOWER RC FORASTIERE AA ETTINGER DS CHEN TL SARTORIUS S GROCHOW LB
Citation: S. Oreilly et al., PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN IN PATIENTS WITH IMPAIRED RENAL-FUNCTION, Journal of clinical oncology, 14(12), 1996, pp. 3062-3073
SEQUENCES OF TOPOTECAN AND CISPLATIN - PHASE-I, PHARMACOLOGICAL, AND IN-VITRO STUDIES TO EXAMINE SEQUENCE DEPENDENCE
Authors: ROWINSKY EK KAUFMANN SH BAKER SD GROCHOW LB CHEN TL PEEREBOOM D BOWLING MK SARTORIUS SE ETTINGER DS FORASTIERE AA DONEHOWER RC
Citation: Ek. Rowinsky et al., SEQUENCES OF TOPOTECAN AND CISPLATIN - PHASE-I, PHARMACOLOGICAL, AND IN-VITRO STUDIES TO EXAMINE SEQUENCE DEPENDENCE, Journal of clinical oncology, 14(12), 1996, pp. 3074-3084
PHARMACOKINETIC, ORAL BIOAVAILABILITY, AND SAFETY STUDY OF FLUOROURACIL IN PATIENTS TREATED WITH 776C85, AN INACTIVATOR OF DIHYDROPYRIMIDINE DEHYDROGENASE
Authors: BAKER SD KHOR SP ADJEI AA DOUCETTE M SPECTOR T DONEHOWER RC GROCHOW LB SARTORIUS SE NOE DA HOHNEKER JA ROWINSKY EK
Citation: Sd. Baker et al., PHARMACOKINETIC, ORAL BIOAVAILABILITY, AND SAFETY STUDY OF FLUOROURACIL IN PATIENTS TREATED WITH 776C85, AN INACTIVATOR OF DIHYDROPYRIMIDINE DEHYDROGENASE, Journal of clinical oncology, 14(12), 1996, pp. 3085-3096
THE EFFECTS OF FOOD AND DIVIDED DOSING ON THE BIOAVAILABILITY OF ORALVINORELBINE
Authors: ROWINSKY EK LUCAS VS HSIEH ALY WARGIN WA HOHNEKER JA LUBEJKO B SARTORIUS SE DONEHOWER RC
Citation: Ek. Rowinsky et al., THE EFFECTS OF FOOD AND DIVIDED DOSING ON THE BIOAVAILABILITY OF ORALVINORELBINE, Cancer chemotherapy and pharmacology, 39(1-2), 1996, pp. 9-16
DEVELOPMENT OF A CANINE CHEMOTHERAPEUTIC MODEL WITH IFOSFAMIDE
Authors: IKEDA K INOUE N FRASSICA FJ DONEHOWER RC TOMITA K CHAO EYS
Citation: K. Ikeda et al., DEVELOPMENT OF A CANINE CHEMOTHERAPEUTIC MODEL WITH IFOSFAMIDE, Laboratory animal science, 46(5), 1996, pp. 503-506
SHOULD ANTICANCER DRUG DOSES BE ADJUSTED IN THE OBESE PATIENT
Authors: BAKER SD GROCHOW LB DONEHOWER RC
Citation: Sd. Baker et al., SHOULD ANTICANCER DRUG DOSES BE ADJUSTED IN THE OBESE PATIENT, Journal of the National Cancer Institute, 87(5), 1995, pp. 333-334
PHASE-I STUDY OF NONREPLICATING AUTOLOGOUS TUMOR-CELL INJECTIONS USING CELLS PREPARED WITH OR WITHOUT GM-CSF GENE TRANSDUCTION IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: BERNS AJM CLIFT S COHEN LK DONEHOWER RC DRANOFF G HAUDA KM JAFFEE EM LAZENBY AJ LEVITSKY HI MARSHALL FF MULLIGAN RC NELSON WG OWENS AH PARDOLL DM PARRY G PARTIN AH PIANTADOSI S SIMONS JW ZABORA JR
Citation: Ajm. Berns et al., PHASE-I STUDY OF NONREPLICATING AUTOLOGOUS TUMOR-CELL INJECTIONS USING CELLS PREPARED WITH OR WITHOUT GM-CSF GENE TRANSDUCTION IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, Human gene therapy, 6(3), 1995, pp. 347-368
PHASE-I AND PHARMACOLOGICAL STUDIES OF PYRAZOLOACRIDINE, A NOVEL DNA INTERCALATING AGENT, ON SINGLE-DOSING AND MULTIPLE-DOSING SCHEDULES
Authors: ROWINSKY EK NOE DA GROCHOW LB SARTORIOUS SE BOWLING MK CHEN TL LUBEJKO BG KAUFMANN SH DONEHOWER RC
Citation: Ek. Rowinsky et al., PHASE-I AND PHARMACOLOGICAL STUDIES OF PYRAZOLOACRIDINE, A NOVEL DNA INTERCALATING AGENT, ON SINGLE-DOSING AND MULTIPLE-DOSING SCHEDULES, Journal of clinical oncology, 13(8), 1995, pp. 1975-1984
PRETREATMENT H-2-RECEPTOR ANTAGONISTS THAT DIFFER IN P450 MODULATION ACTIVITY - COMPARATIVE EFFECTS ON PACLITAXEL CLEARANCE RATES AND NEUTROPENIA
Authors: SLICHENMYER WJ DONEHOWER RC CHEN TL BOWLING MK MCGUIRE WP ROWINSKY EK
Citation: Wj. Slichenmyer et al., PRETREATMENT H-2-RECEPTOR ANTAGONISTS THAT DIFFER IN P450 MODULATION ACTIVITY - COMPARATIVE EFFECTS ON PACLITAXEL CLEARANCE RATES AND NEUTROPENIA, Cancer chemotherapy and pharmacology, 36(3), 1995, pp. 227-232
Risultati: 1-25 | 26-45